Valiant Laboratories profit and loss

Latest FY26

Revenue: ₹237cr+78.0% on FY25
EBITDA: ₹6.4cr−₹4.7 cr in FY25
Net profit: −₹3.3cr−₹2.2 cr in FY25
EPS: −₹0.51−₹0.51 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

Expenses
	306	237	133	182
	2.5	2.3	5.4	9.7
	308	240	139	192
	218	191	112	169
	16.0	9.0	0.6	−0.5
	−8.4	−2.7	3.9	−0.7
	8.4	7.0	4.4	4.3
	2.9	1.9	0.2	0.1
	8.4	6.0	2.1	2.0
	39.1	26.9	17.1	17.9
	284	239	140	193
	33.3	6.4	−4.7	−8.4
	24.9	0.4	−6.8	−10.4
Profit
	24.5	0.8	−1.5	−0.8
	24.5	0.8	−1.5	−0.8
	5.4	1.6	0.1	−1.0
	3.1	2.4	0.6	−0.1
	8.5	4.0	0.7	−1.1
	16.0	−3.3	−2.2	0.3
	16.0	−3.3	−2.2	0.3
	0.0	0.0	−0.0	0.2
	16.0	−3.3	−2.2	0.5
	16.0	−3.3	−2.2	0.3
Per share
	₹2.95	−₹0.51	−₹0.51	₹0.13
	₹2.84	−₹0.51	−₹0.51	₹0.13
Other comprehensive income — detail
	—	0.0	−0.0	—
	—	—	−0.0	0.2
	—	−0.0	0.0	—
	—	—	—	0.1
	16.0	−3.3	−2.2	0.5
Per share — as-filed variants
	₹2.95	−₹0.51	−₹0.51	₹0.13
	₹2.84	−₹0.51	−₹0.51	₹0.13
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	80.7	40.3	16.8	13.8
	26.4%	17.0%	12.6%	7.6%
Adjusted (ex-exceptional items) — derived
	24.5	0.8	−1.5	−0.8
	16.0	−3.3	−2.2	0.3
	₹2.95	−₹0.51	−₹0.51	₹0.13

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VALIANTLAB₹125.82

Valiant Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersALBERTDAVD HALEOSLABS ZIMLAB MEDICO MEDICAMEQ ANUHPHR AHCL WANBURYMcap ₹683 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	182.1	133.4	237.5	305.9
Other Income	9.7	5.4	2.3	2.5
Total Income	191.7	138.8	239.8	308.5
Expenses
+ Cost of Materials Consumed	169.4	112.2	190.8	217.7
+ Purchases of Stock-in-Trade	-0.5	0.6	9.0	16.0
+ Changes in Inventories	-0.7	3.9	-2.7	-8.4
+ Employee Benefit Expense	4.3	4.4	7.0	8.4
+ Finance Costs	0.1	0.2	1.9	2.9
+ Depreciation & Amortisation	2.0	2.1	6.0	8.4
+ Other Expenses	17.9	17.1	26.9	39.1
Total Expenses	192.5	140.3	239.0	283.9
EBITDA	-8.4	-4.7	6.4	33.3
EBIT	-10.4	-6.8	0.4	24.9
Profit
PBT before Exceptional Items	-0.8	-1.5	0.8	24.5
Pretax Income	-0.8	-1.5	0.8	24.5
+ Current Tax	-1.0	0.1	1.6	5.4
+ Deferred Tax	-0.1	0.6	2.4	3.1
Tax Expense	-1.1	0.7	4.0	8.5
Net Income	0.3	-2.2	-3.3	16.0
+ Net Income — Continuing Ops	0.3	-2.2	-3.3	16.0
+ Other Comprehensive Income	0.2	-0.0	0.0	0.0
Total Comprehensive Income	0.5	-2.2	-3.3	16.0
Net Income to Common	0.3	-2.2	-3.3	16.0
Per Share
Basic EPS	0.13	-0.51	-0.51	2.95
Diluted EPS	0.13	-0.51	-0.51	2.84
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	-0.0	0.0	—
+ Items NOT to be Reclassified to P&L	0.2	-0.0	—	—
+ Tax on Items NOT to be Reclassified	—	0.0	-0.0	—
+ Tax on Items NOT to be Reclassified — alt tag	0.1	—	—	—
Comprehensive Income — Owners of Parent	0.5	-2.2	-3.3	16.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.13	-0.51	-0.51	2.95
Diluted EPS — Continuing Operations	0.13	-0.51	-0.51	2.84
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	13.8	16.8	40.3	80.7
Gross Margin %	7.58	12.58	16.97	26.39
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-0.8	-1.5	0.8	24.5
Net Income Adj (tax-effected)	0.3	-2.2	-3.3	16.0
EPS Adj	0.13	-0.51	-0.51	2.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00
Paid Up Equity Capital	43.5	43.5	54.3	54.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.